Chimeric Antibodies Against Hepatitis B e-Antigen

The invention relates to recombinant chimeric rabbit/human monoclonal antibody fragments (Fabs) against hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis is the seventh leading cause of death worldwide. Hepatitis B core antigen (HBcAg) forms an icosahedral structure containing the viral genome. Both the HBcAg and the HBeAg of interest here are expressed by two different start codons of the viral C gene. Unlike the related HBcAg which activates type 1 T helper (Th1) cells leading to immune attack, the HBeAg activates Th2 cells which promote immune tolerance. The long-term persistence of HBeAg is associated with the development of hepatocellular carcinoma. Conversely, HBeAg seroconversion (from HBeAg carrier to anti-HBeAg carrier) is a marker for successful therapy of chronically infected patients. The presently phage display engineered antibody Fab me6 shows higher sensitivity and selectivity against HBeAg compared to three commercial diagnostics kits tested; additionally, it also inhibits capsid assembly which is essential for viral replication; furthermore, it can also be fully humanized and has potential for anti-hepatitis B virus therapeutic interventions.

Potential Commercial Applications: Competitive Advantages:
  • Hepatocellular carcinoma prophylaxis
  • Hepatitis B diagnostics and therapy


Paul Wingfield (NIAMS)  ➽ more inventions...

Norman Watts (NIAMS)  ➽ more inventions...

Alasdair Steven (NIAMS)  ➽ more inventions...

Intellectual Property:
US Application No. 62/534,603

Collaboration Opportunity:

The National Institute of Arthritis and Musculoskeletal and Skin Diseases seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate this technology. For further information, please contact Cecilia Pazman, PhD, Technology Development Specialist, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute, Phone: 301-594-4273; Email:

Licensing Contact:
Michael Shmilovich, J.D.
Phone: 301-435-5019

OTT Reference No: E-192-2017/0
Updated: Jan 31, 2018